文献速递脑血管病神经重症与神经感染

急性点征阳性脑出血早期血肿扩大的时间进程:SPOTLIGHT随机临床试验的预设分析

Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial.
PubMed 文献 · Stroke · 2023-02-09

SPOTLIGHT试验将点征阳性急性脑出血患者随机分配至rFVIIa(80 μg/kg)或安慰剂组,在发病6小时内给药,未显著减少血肿扩大。本预设分析纳入50例患者(44例有早期给药后CT),发现大部分血肿扩大发生在基线CT至早期给药后CT之间,调整后rFVIIa组血肿增长为安慰剂组的0.998倍(95%CI 0.71-1.43;P=0.99),作者认为未来止血试验需更早治疗。

要点

  • 点征阳性脑出血患者中,大部分血肿扩大发生在基线CT至早期给药后CT之间。
  • 调整后rFVIIa组血肿增长为安慰剂组的0.998倍(95%CI 0.71-1.43;P=0.99),无显著关联。
  • 作者认为未来止血试验需从发病更早开始治疗,并尽量缩短基线CT至给药的时间。

核心结论

  • 在SPOTLIGHT试验中,调整后血肿体积增长与Factor VIIa治疗无关。
  • 大部分血肿扩大发生在基线CT与早期给药后CT之间,限制了止血治疗的潜在效果。
  • 作者认为未来止血试验必须从发病更早开始治疗脑出血患者,并尽量缩短基线CT至给药的时间。

研究设计与样本

  • SPOTLIGHT试验的预设分析,患者为CT血管造影点征阳性的急性脑出血,随机分配至rFVIIa(80 μg/kg)或安慰剂组,在发病6小时内给药。
  • 共纳入50例患者,其中44例有早期给药后CT扫描。
  • 在基线CT、早期给药后CT和24小时CT上测量血肿体积,计算总血肿体积(脑出血+脑室出血)变化。

主要发现

  • 发病至基线CT的中位时间(四分位距)为1.4小时(1.2-2.6)。
  • 基线CT至研究药物的中位时间为62.5(55-80)分钟,研究药物至早期给药后CT的中位时间为19(14.5-30)分钟。
  • 基线CT至早期给药后CT的总血肿体积中位变化:rFVIIa组增加10.0 mL(-0.7至18.5),安慰剂组增加5.4 mL(1.8-8.3)(P=0.96)。
  • 早期给药后CT至随访扫描的中位体积变化:rFVIIa组0.6 mL(-2.6至8.3),安慰剂组0.7 mL(-1.6至2.1)(P=0.98)。
  • 早期给药后CT至24小时扫描总血肿体积减少者占44.2%(rFVIIa组38.9%,安慰剂组48%)。

临床怎么用

  • 作者认为未来止血试验必须从发病更早开始治疗脑出血患者,并尽量缩短基线CT至给药的时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the SPOTLIGHT trial (Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy), patients with a computed tomography (CT) angiography spot-sign positive acute intracerebral hemorrhage were randomized to rFVIIa (recombinant activated factor VIIa; 80 μg/kg) or placebo within 6 hours of onset, aiming to limit hematoma expansion. Administration of rFVIIa did not significantly reduce hematoma expansion. In this prespecified analysis, we aimed to investigate the impact of delays from baseline imaging to study drug administration on hematoma expansion. METHODS: Hematoma volumes were measured on the baseline CT, early post-dose CT, and 24 hours CT scans. Total hematoma volume (intracerebral hemorrhage+intraventricular hemorrhage) change between the 3 scans was calculated as an estimate of how much hematoma expansion occurred before and after studying drug administration. RESULTS: Of the 50 patients included in the trial, 44 had an early post-dose CT scan. Median time (interquartile range) from onset to baseline CT was 1.4 hours (1.2-2.6). Median time from baseline CT to study drug was 62.5 (55-80) minutes, and from study drug to early post-dose CT was 19 (14.5-30) minutes. Median (interquartile range) total hematoma volume increased from baseline CT to early post-dose CT by 10.0 mL (-0.7 to 18.5) in the rFVIIa arm and 5.4 mL (1.8-8.3) in the placebo arm (P=0.96). Median volume change between the early post-dose CT and follow-up scan was 0.6 mL (-2.6 to 8.3) in the rFVIIa arm and 0.7 mL (-1.6 to 2.1) in the placebo arm (P=0.98). Total hematoma volume decreased between the early post-dose CT and 24-hour scan in 44.2% of cases (rFVIIa 38.9% and placebo 48%). The adjusted hematoma growth in volume immediately post dose for FVIIa was 0.998 times that of placebo ([95% CI, 0.71-1.43]; P=0.99). The hourly growth in FFVIIa was 0.998 times that for placebo ([95% CI, 0.994-1.003]; P=0.50; Table 3). CONCLUSIONS: In the SPOTLIGHT trial, the adjusted hematoma volume growth was not associated with Factor VIIa treatment. Most hematoma expansion occurred between the baseline CT and the early post-dose CT, limiting any potential treatment effect of hemostatic therapy. Future hemostatic trials must treat intracerebral hemorrhage patients earlier from onset, with minimal delay between baseline CT and drug administration. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01359202.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Al-Ajlan FS, Gladstone DJ, Song D, et al. Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial. Stroke. 2023. PMID: 36756899. doi:10.1161/STROKEAHA.121.038475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。